GSK (GSK, Financials) said Wednesday it will invest at least $30 billion in U.S. operations over the next five years, expanding research, development and manufacturing. The announcement coincided with President Donald Trump's state visit to the U.K.
The investment includes $1.2 billion for advanced manufacturing, artificial intelligence and digital technologies. GSK said the spending will help build new biologics facilities and upgrade existing plants in Pennsylvania, North Carolina, Maryland and Montana.
CEO Emma Walmsley said the commitment reflects the company's dual footprint in both the U.K. and U.S., and aims to strengthen GSK's American supply chain and clinical trial presence.
The plan follows similar moves by global drugmakers. AstraZeneca recently pledged $50 billion for U.S. manufacturing and research by 2030, while Novartis, Sanofi, Roche, Eli Lilly and Johnson & Johnson have also stepped up U.S. investments.
Trump's visit has already brought new technology commitments from Microsoft, Nvidia, Google, OpenAI and Salesforce in the U.K., signaling closer economic ties. But several pharmaceutical companies have scaled back U.K. projects, citing concerns over pricing and policy support.
GSK's new U.S. investment will focus heavily on biologics production, including cancer and respiratory medicines, and expanded digital capabilities across its supply chain.
